These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 23136592)

  • 1. Selection of chemotherapy for glioblastoma expressing O(6)-methylguanine-DNA methyltransferase.
    Iwadate Y; Matsutani T; Hasegawa Y; Shinozaki N; Oide T; Tanizawa T; Nakatani Y; Saeki N; Fujimoto S
    Exp Ther Med; 2010 Jan; 1(1):53-57. PubMed ID: 23136592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. O6-methylguanine DNA methyltransferase expression in tumor cells predicts outcome of radiotherapy plus concomitant and adjuvant temozolomide therapy in patients with primary glioblastoma.
    Watanabe R; Nakasu Y; Tashiro H; Mitsuya K; Ito I; Nakasu S; Nakajima T
    Brain Tumor Pathol; 2011 Apr; 28(2):127-35. PubMed ID: 21331613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemical analysis of O6-methylguanine-DNA methyltransferase (MGMT) protein expression as prognostic marker in glioblastoma patients treated with radiation therapy with concomitant and adjuvant Temozolomide.
    Younis SG; Khedr RA; El-Shorbagy SH
    J Egypt Natl Canc Inst; 2016 Mar; 28(1):23-30. PubMed ID: 26682634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of chemotherapy-induced DNA repair on oncolytic herpes simplex viral replication.
    Aghi M; Rabkin S; Martuza RL
    J Natl Cancer Inst; 2006 Jan; 98(1):38-50. PubMed ID: 16391370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. O(6) -methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherapy with concomitant and adjuvant temozolomide.
    Lechapt-Zalcman E; Levallet G; Dugué AE; Vital A; Diebold MD; Menei P; Colin P; Peruzzy P; Emery E; Bernaudin M; Chapon F; Guillamo JS
    Cancer; 2012 Sep; 118(18):4545-54. PubMed ID: 22359215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
    Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
    Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Somatic mutations in glioblastoma are associated with methylguanine-DNA methyltransferase methylation.
    McDonald KL; Tabone T; Nowak AK; Erber WN
    Oncol Lett; 2015 May; 9(5):2063-2067. PubMed ID: 26137013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA repair in personalized brain cancer therapy with temozolomide and nitrosoureas.
    Kaina B; Christmann M
    DNA Repair (Amst); 2019 Jun; 78():128-141. PubMed ID: 31039537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Temozolomide-mediated radiation enhancement in glioblastoma: a report on underlying mechanisms.
    Chakravarti A; Erkkinen MG; Nestler U; Stupp R; Mehta M; Aldape K; Gilbert MR; Black PM; Loeffler JS
    Clin Cancer Res; 2006 Aug; 12(15):4738-46. PubMed ID: 16899625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. O(6)-Methylguanine DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression is correlated with progression-free survival in patients with glioblastoma.
    Sonoda Y; Yokosawa M; Saito R; Kanamori M; Yamashita Y; Kumabe T; Watanabe M; Tominaga T
    Int J Clin Oncol; 2010 Aug; 15(4):352-8. PubMed ID: 20232102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oligodendrogliomas lacking O6-methylguanine-DNA-methyltransferase expression.
    Buccoliero AM; Arganini L; Ammannati F; Gallina P; Di Lorenzo N; Mennonna P; Taddei GL
    J Chemother; 2005 Jun; 17(3):321-6. PubMed ID: 16038527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is the absolute value of O(6)-methylguanine-DNA methyltransferase gene messenger RNA a prognostic factor, and does it predict the results of treatment of glioblastoma with temozolomide?
    Tanaka S; Akimoto J; Narita Y; Oka H; Tashiro T
    J Neurosurg; 2014 Oct; 121(4):818-26. PubMed ID: 25105699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide.
    Hegi ME; Diserens AC; Godard S; Dietrich PY; Regli L; Ostermann S; Otten P; Van Melle G; de Tribolet N; Stupp R
    Clin Cancer Res; 2004 Mar; 10(6):1871-4. PubMed ID: 15041700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glycogen synthase kinase 3β inhibition sensitizes human glioblastoma cells to temozolomide by affecting O6-methylguanine DNA methyltransferase promoter methylation via c-Myc signaling.
    Pyko IV; Nakada M; Sabit H; Teng L; Furuyama N; Hayashi Y; Kawakami K; Minamoto T; Fedulau AS; Hamada J
    Carcinogenesis; 2013 Oct; 34(10):2206-17. PubMed ID: 23715499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas.
    Felsberg J; Thon N; Eigenbrod S; Hentschel B; Sabel MC; Westphal M; Schackert G; Kreth FW; Pietsch T; Löffler M; Weller M; Reifenberger G; Tonn JC;
    Int J Cancer; 2011 Aug; 129(3):659-70. PubMed ID: 21425258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased expression of the histone H3 lysine 4 methyltransferase MLL4 and the histone H3 lysine 27 demethylase UTX prolonging the overall survival of patients with glioblastoma and a methylated MGMT promoter.
    Kim J; Lee SH; Jang JH; Kim MS; Lee EH; Kim YZ
    J Neurosurg; 2017 May; 126(5):1461-1471. PubMed ID: 27367247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of O6-methylguanine-DNA methyltransferase protein expression in patients with recurrent glioblastoma treated with temozolomide.
    Nagane M; Kobayashi K; Ohnishi A; Shimizu S; Shiokawa Y
    Jpn J Clin Oncol; 2007 Dec; 37(12):897-906. PubMed ID: 18156172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between expression of O6-methylguanine-DNA methyltransferase, glutathione-S-transferase pi in glioblastoma and the survival of the patients treated with nimustine hydrochloride: an immunohistochemical analysis.
    Anda T; Shabani HK; Tsunoda K; Tokunaga Y; Kaminogo M; Shibata S; Hayashi T; Iseki M
    Neurol Res; 2003 Apr; 25(3):241-8. PubMed ID: 12739231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [O6-methylguanine-DNA-methyltransferase (MGMT) expression in patients with glioblastoma multiforme].
    Jiménez D; Matamala JM; Chiti A; Vergara C; Tissera C; Melo R; Cartier L
    Rev Med Chil; 2018 Jan; 146(1):7-14. PubMed ID: 29806672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunohistochemical evaluation of O6 -methylguanine DNA methyltransferase (MGMT) expression in 117 cases of glioblastoma.
    Miyazaki M; Nishihara H; Terasaka S; Kobayashi H; Yamaguchi S; Ito T; Kamoshima Y; Fujimoto S; Kaneko S; Katoh M; Ishii N; Mohri H; Tanino M; Kimura T; Tanaka S
    Neuropathology; 2014 Jun; 34(3):268-76. PubMed ID: 24397721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.